S&P lowers NBTY credit rating
This article was originally published in The Tan Sheet
Standard & Poor's lowers the vitamin and supplement maker's credit rating from 'BB' to 'B+' in light of the Carlyle Group's planned acquisiton. The change "reflects weakened credit measures" from Carlyle's proposed capital structure for NBTY, including about $2 billion in additional debt, analyst Jacqueline Hui said in an Aug. 26 release. But the rating service deemed NBTY "stable," saying the company likely will "maintain pro forma credit metrics in line with the current rating over the near term." NBTY remains in a strong market position, but the supplement market is highly competitive, S&P noted. Carlyle announced its $3.8 billion acqusition July 15 (1"The Tan Sheet" July 19, 2010)
You may also be interested in...
The Carlyle Group's planned acquisition of NBTY for $3.8 billion may not be the only private equity offer to surface for the dietary supplement giant
High court is to determine whether the government can dismiss an FCA complaint after initially declining to take it over. In recent years, the government has dismissed numerous qui tam suits against pharma companies in which it did not intervene.
Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.